BioSpace News Archive

Drug Development

BMS, Synairgen Regroup After Trials Miss Primary Endpoints

Monday woes were shared by Bristol Myers Squibb and Synairgen, as their clinical trial candidates failed to perform as expected.

May 16, 2022
·
3 min read
·
Jazmine Colatriano M.S.
Business

Kriya Therapeutics Scores $270 Million to Support Gene Therapy Pipeline

Kriya Therapeutics secured $270 million that will be used to advance its fully integrated gene therapy pipeline and expand engineering, manufacturing and computation.

May 16, 2022
·
2 min read
·
Alex Keown
Business

Akebia Terminates License Agreements with Otsuka

Akebia Therapeutics’s partner Otsuka Pharmaceutical Co. announced plans to terminate its global license agreements with Akebia for vadadustat.

May 16, 2022
·
2 min read
·
Mark Terry
Deals

KemPharm Acquires Majority of Orphazyme Assets Under In-Court Restructuring

Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company’s assets and operations.

May 16, 2022
·
3 min read
·
Hannah Chudleigh
Researchers Continue to Build Toolbox as May Recognizes ALS

In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.

May 16, 2022
·
6 min read
·
Heather McKenzie
Business

Sofinnova Nets $1B+ from Apollo to Accelerate Biotech Growth

Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.

May 16, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

Orna Proves Concept in Preclinical Oncology and DMD Models

Orna announced first-ever data from its lead isCAR program that validates both the technology and its LNP delivery platform. BioSpace spoke with ORNA CEO Tom Barnes.

May 16, 2022
·
3 min read
·
Heather McKenzie
Business

AbbVie, AstraZeneca See Value in what Cugene, Proteros Have to Offer

Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.

May 16, 2022
·
3 min read
·
Mark Terry
Latest Count has Mysterious Pediatric Hepatitis at 450 Cases Worldwide

The European Center for Disease Prevention and Control said the number of unusual pediatric hepatitis cases has reached 450, double the number reported two weeks ago.

May 16, 2022
·
3 min read
·
Mark Terry
Policy

Seagen CEO Resigns Following Domestic Violence Allegations

Clay Siegall resigned his role as president, CEO and a member of the board of directors of Seagen following domestic violence allegations. Roger Dansey will serve as interim CEO.

May 16, 2022
·
2 min read
·
Alex Keown